




RealRate

# PHARMACEUTICAL 2023

MEI Pharma Inc.  
Rank 276 of 446





RealRate

# PHARMACEUTICAL 2023

MEI Pharma Inc.  
Rank 276 of 446



The relative strengths and weaknesses of MEI Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEI Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 35% points. The greatest weakness of MEI Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 24%, being 20% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	167,126
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,443
Liabilities, Non-Current	8,771
Other Assets	9,054
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	92,213
Other Net Income	21,030
Other Revenues	40,697
Property and Equipment	1,660
Research and Development	85,641
Selling, General and Administrative Expense	30,540

Output Variable	Value in 1000 USD
Assets	177,840
Liabilities	125,427
Expenses	116,181
Revenues	40,697
Stockholders Equity	52,413
Net Income	-54,454
Comprehensive Net Income	-54,454
Economic Capital Ratio	24%